Category - Developments

Developments

Ocutrx Vision named to StartUp City’s list of promising wearable startups

Closely-held Ocutrx Vision Technologies was named to StartUp City’s annual list of the 15 most promising wearable technology startups for its Oculenz AR (augmented reality) glasses for low vision patients. Oculenz is...

February 5, 2019

Developments

Titan Pharma posts double-digit increase in Probuphine shipments

Titan Pharmaceuticals (NASDAQ:TTNP) updated the U.S. commercial relaunch of its Probuphine implant for the treatment for opioid use disorder, reporting that it achieved a double-digit increase in product shipments in...

February 1, 2019

Developments

FDA performs pre-approval inspection of IntelGenx plant for RIZAPORT

The FDA has performed a pre-approval inspection of IntelGenx’s (TSXV:IGX; OTCQX:IGXT) Health Canada-certified cGMP manufacturing facility in Montreal in connection with the company’s NDA for RIZAPORT, a VersaFilm oral...

January 30, 2019

Developments

ArcherDX acquires genetic testing firm Baby Genes

Closely-held ArcherDX acquired genetic testing lab, Baby Genes. It will operate as a wholly-owned subsidiary under the name ArcherDX Clinical Services, and continue to market a suite of existing newborn genetic testing...

January 30, 2019

Developments

Lutronic Vision initiates preclinical laser trial for dry AMD

Closely-held Lutronic Vision initiated a preclinical trial to determine the optimal setting for its R:GEN laser for the treatment of the dry form of age-related macular degeneration (AMD). At the conclusion of the...

January 30, 2019

Developments

Triphase Accelerator options leukemia compound to Celgene

Closely-held Triphase Accelerator entered a new strategic partnership with Celgene (NASDAQ:CELG) to develop a preclinical therapeutic compound, TRPH-395, for the treatment of leukemia and other blood cancers...

January 29, 2019

Developments

IntelGenx updates Phase 2a Montelukast VersaFilm trial in AD

IntelGenx (TSXV:IGX; OTCQX:IGXT) updated its Phase 2a study of Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s disease (AD). To date, seven study sites across Canada have randomized eight subjects...

January 23, 2019

Developments

Rigel Pharma in pact with Grifols to commercialize fostamatinib in Europe

Rigel Pharmaceuticals (NASDAQ:RIGL) entered an exclusive license and supply agreement with Grifols (MCE:GRF; MCE:GRF.P; NASDAQ:GRFS) of Spain to commercialize fostamatinib disodium hexahydrate in all potential...

January 23, 2019

Developments

Blood protein may predict progression of pre-symptomatic Alzheimer’s disease

Researchers in Germany have identified a blood protein marker that can predict the progression of neurodegenerative diseases, including Alzheimer’s disease (AD). The test can detect thisbiomarker in the blood up to 16...

January 23, 2019

Developments

Vessi Medical posts positive preclinical surface cryoablation results for bladder cancer

Closely-held Vessi Medical, a member of Israel’s Trendlines Group (OTCQX:TRNLY; SGX:42T), reported a successful animal study demonstrating the use of its surface cryoablation therapy inside the urinary bladder...

January 22, 2019

Category - Developments

Subscribe